Patents by Inventor Michael B. Brenner

Michael B. Brenner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
    Patent number: 11534496
    Abstract: This disclosure provides methods and compositions for detecting Tph cells and/or reducing the number (or frequency) and/or activity of such cells in order to provide therapeutic benefit to a subject having or at risk of developing an autoantibody-associated condition such as an autoantibody-associated autoimmune disease.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: December 27, 2022
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Deepak A. Rao
  • Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
    Patent number: 11097005
    Abstract: Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: August 24, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Sook Kyung Chang, Lydia Lynch
  • COMPOSITIONS AND METHODS RELATING TO T PERIPHERAL HELPER CELLS IN AUTOANTIBODY-ASSOCIATED CONDITIONS
    Publication number: 20190298850
    Abstract: This disclosure provides methods and compositions for detecting Tph cells and/or reducing the number (or frequency) and/or activity of such cells in order to provide therapeutic benefit to a subject having or at risk of developing an autoantibody-associated condition such as an autoantibody-associated autoimmune disease.
    Type: Application
    Filed: December 6, 2016
    Publication date: October 3, 2019
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Deepak A. Rao
  • USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS
    Publication number: 20170360934
    Abstract: Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.
    Type: Application
    Filed: December 15, 2015
    Publication date: December 21, 2017
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Sook Kyung Chang, Lydia Lynch
  • DETECTION AND TREATMENT OF NON-DERMAL FIBROSIS
    Publication number: 20150266955
    Abstract: The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis.
    Type: Application
    Filed: October 1, 2014
    Publication date: September 24, 2015
    Applicants: The Brigham and Women's Hospital, Inc., Board of Regents, The University of Texas System
    Inventors: SANDEEP K. AGARWAL, MICHAEL B. BRENNER
  • Detection and treatment of non-dermal fibrosis
    Patent number: 8877188
    Abstract: The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 4, 2014
    Assignees: The Brigham and Women's Hospital, Inc., Board of Regents, The University of Texas System
    Inventors: Sandeep K. Agarwal, Michael B. Brenner
  • TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20130209476
    Abstract: A method is provided for treating certain inflammatory disorders by inhibiting cadherin-11 function using a cadherin-11 antagonist.
    Type: Application
    Filed: June 3, 2011
    Publication date: August 15, 2013
    Applicant: The Brigham and Women's Hospital Inc.
    Inventors: Michael B. Brenner, Erika Heidi Noss, Sook Kyung Chang
  • DETECTION AND TREATMENT OF NON-DERMAL FIBROSIS
    Publication number: 20110274703
    Abstract: The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis.
    Type: Application
    Filed: May 4, 2011
    Publication date: November 10, 2011
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: SANDEEP K. AGARWAL, DANIEL J. SCHNEIDER, MICHAEL B. BRENNER
  • Apolipoprotein E as an adjuvant for lipid antigens
    Patent number: 7608246
    Abstract: The present invention is directed to pharmaceutical compositions that contain a combination of apolipoprotein E and an antigenic lipid. The compositions may be administered to a subject for the purpose of inducing an immune response against the lipid and in immunization protocols.
    Type: Grant
    Filed: September 5, 2006
    Date of Patent: October 27, 2009
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Peter van den Elzen, Michael B. Brenner
  • Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
    Patent number: 7589074
    Abstract: A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: September 15, 2009
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Xavier Valencia
  • Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
    Patent number: 7488478
    Abstract: A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: February 10, 2009
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Xavier Valencia
  • Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
    Publication number: 20080214487
    Abstract: A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.
    Type: Application
    Filed: November 21, 2007
    Publication date: September 4, 2008
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Xavier Valencia
  • Presentation of hydrophobic antigens to T-cells by CD1 molecules
    Patent number: 7063844
    Abstract: Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including: methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample; methods for isolating such CD1-presented antigens and isolated antigens; vaccines containing CD1-presented antigens and vaccination methods; methods of blocking CD1 antigen presentation; methods of identifying and/or isolating CD1 blocking agents and the isolated CD1 blocking agents; methods of inducing CD1 expression; and T-cells for use in the methods disclosed herein.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: June 20, 2006
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Steven A. Porcelli, Michael B. Brenner, Evan M. Beckman, Stephen T. Furlong
  • Methods and compositions for modulating heterotypic E-cadherin interactions with T lymphocytes
    Patent number: 7029676
    Abstract: The present invention relates to methods and compositions for modulating the heterotypic adhesion between E-cadherin expressing cells and T lymphocytes. Monoclonal antibodies which specifically bind to E-cadherin and isolated peptides which mimic the binding function of E-cadherin also are provided. The antibodies and peptides are useful in screening assays to identify pharmaceutical lead compounds which are capable of modulating adhesion between T lymphocytes and E-cadherin expressing cells. Methods and pharmaceutical compositions for modifying the mucosal immune response of a subject also are provided.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: April 18, 2006
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Karyn L. Cepek
  • Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
    Patent number: 6964768
    Abstract: A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: November 15, 2005
    Assignee: The Brigham & Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Xavier Valencia
  • Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
    Patent number: 6787136
    Abstract: A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: September 7, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Xavier Valencia
  • Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
    Publication number: 20040009176
    Abstract: A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.
    Type: Application
    Filed: June 9, 2003
    Publication date: January 15, 2004
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Xavier Valencia
  • Novel integrin alpha subunit
    Publication number: 20030133933
    Abstract: The present invention relates to a novel integrin &agr;E subunit and its functional equivalents. The invention further includes pharmaceutical compositions containing the isolated peptides, oligonucleotides encoding the peptides, vectors containing the oligonucleotides, and cell lines transfected with the vectors.
    Type: Application
    Filed: June 21, 2002
    Publication date: July 17, 2003
    Inventors: Michael B. Brenner, Christina M. Parker
  • Control of lymphocyte localization by LEEP-CAM activity
    Publication number: 20030049259
    Abstract: A novel cell surface glycoprotein, LEEP-CAM, is disclosed. This invention further provides methods for treating inflammatory disorders in mammals through the administration of compositions which are modulators of LEEP-CAM activity. Antibodies are also disclosed which prevent LEEP-CAM-mediated migration of lymphocytes into epithelial layers of cells.
    Type: Application
    Filed: January 22, 2002
    Publication date: March 13, 2003
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Christina M. Parker, Michael P. Schon
  • Methods and compositions for modulating heterotypic E-cadherin interactions with T lymphocytes
    Publication number: 20020192724
    Abstract: The present invention relates to methods and compositions for modulating the heterotypic adhesion between E-cadherin expressing cells and T lymphocytes. Monoclonal antibodies which specifically bind to E-cadherin and isolated peptides which mimic the binding function of E-cadherin also are provided. The antibodies and peptides are useful in screening assays to identify pharmaceutical lead compounds which are capable of modulating adhesion between T lymphocytes and E-cadherin expressing cells. Methods and pharmaceutical compositions for modifying the mucosal immune response of a subject also are provided.
    Type: Application
    Filed: June 7, 2002
    Publication date: December 19, 2002
    Inventors: Michael B. Brenner, Karyn L. Cepek